Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease (ADMIRE-CD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01541579|
Recruitment Status : Completed
First Posted : March 1, 2012
Last Update Posted : November 29, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Crohn's Disease||Other: Cx601 Other: Saline solution||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||278 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess Efficacy and Safety of Expanded Allogeneic Adipose-derived Stem Cells (eASCs) for the Treatment of Perianal Fistulising Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period up to 104 Weeks.|
|Study Start Date :||July 2012|
|Actual Primary Completion Date :||July 2015|
|Actual Study Completion Date :||November 2016|
Experimental: Treatment Arm
Cx601 is a cell suspension in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.
120 million cells administered by intralesional injection.
Placebo Comparator: Placebo-control group
Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.
Other: Saline solution
24 mL saline solution by intralesional injection
- Combine remission of perianal fistulising Crohn's [ Time Frame: 24 weeks ]Combined Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings (EO) that were draining at baseline despite gentle finger compression at week 24, and absence of collections > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI assessment by week 24.
- Efficacy Assessment by week 24 [ Time Frame: 24 weeks ]
- Clinical Remission (CR) defined as closure of all treated EO that were draining at baseline despite gentle finger compression, as clinically assessed
- Response defined as closure of at least 50% of all treated EO that were draining at baseline, as clinically assessed
- Time to Clinical Remission (time from treatment start to 1st visit with closure of all treated EO as described above)
- Time to Response (time from treatment start to 1st visit with closure of at least 50% of all treated EO as described above)
- Relapse defined, in patients with CR at previous visit, as reopening of any of the treated EO with active drainage, or the development of a perianal collection > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI
- Time to Relapse in patients with CR (time from CR to 1st visit with reopening of any of the treated EO as described above)
- Severity of the perianal CD, assessed with the PDAI
- QoL assessed by IBDQ
- CDAI score
- Van Assche
- Efficacy Assessment by week 52 [ Time Frame: 52 weeks ]
- Combined Remission of perianal fistulising Crohn's disease at week 52 (as defined for week 24)
- Clinical Remission defined as the closure of all treated external openings that were draining at baseline despite gentle finger compression, as clinically assessed at week 52
- Response defined as closure of at least 50% of all treated external openings that were draining at baseline, as clinically assessed at week 52
- Time to Combined Remission by week 52 (as defined for week 24)
- Time to Clinical Remission by week 52 (as defined for week 24)
- Time to Response by week 52 (as defined for week 24)
- Relapse by week 52 in patients with Combined Remission at week 24 (as defined for week 24)
- Time to Relapse by week 52 in patients with Combined Remission at week 24 (as defined for week 24)
- Severity of the perianal Crohn's disease up to week 52 assessed PDAI
- QoL up to week 52 by the IBDQ
- CDAI score up to week 52
- Van Assche score up to week 52
- Efficacy Assessment by week 104 [ Time Frame: 104 Weeks ]
- Clinical Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings that were draining at baseline despite gentle finger compression at week 104
- Relapse by week 104 in patients with Combined Remission at week 52, defined as reopening of any of the treated external openings with active drainage as clinically assessed
- Time to Relapse by week 104 in patients with Combined Remission at week 52 (defined as time from Combined Remission to first visit with reopening of any of the treated external openings with active drainage as clinically assessed)
- Severity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI) up to week 104
- Quality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ) up to week 104
- CDAI score up to week 104
- Safety analysis throughout the study: [ Time Frame: week 24, 52 and 104 ]
- Adverse events including: Treatment emergent Adverse Events (TEAEs), TEAEs related to study treatment, Treatment emergent Serious Adverse Events (TESAEs), TESAEs related to study treatment, TEAEs leading to study withdrawal, adverse events related to surgical procedure(s) to provide study treatment, deaths Only SAEs will be reported during the 2nd follow-up period between week 52 and week 104.
- Physical examination
- Vital signs
- Laboratory tests (biochemistry, haematology, urinalysis)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
The reference population will consist of patients with perianal fistulising Crohn´s disease refractory to at least one of the following treatments: antibiotics, immunosuppressants or anti-tumor necrosis factor (TNF). Naïve patients are excluded, and those patients refractory to antibiotics will represent less than 25% of the total recruited patients.
All of them must comply with the following inclusion criteria:
- Signed informed consent.
- Patients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria.
Presence of complex perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the inclusion. A complex perianal fistula is defined as a fistula that met one or more of the following criteria during its evolution:
- High inter-sphincteric, trans-sphincteric, extra-sphincteric or supra-sphincteric.
- Presence of ≥ 2 external openings (tracts).
- Associated collections
- Non-active or mildly active luminal CD defined by a CDAI ≤ 220.
- Patients of either sex aged 18 years or older
- Good general state of health according to clinical history and a physical examination.
- For women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin (hCG)). Both men and women should use appropriate birth control methods defined by the investigator.
- Presence of dominant luminal active Crohn's disease requiring immediate therapy.
- CDAI >220.
- Concomitant rectovaginal fistulas
- Patient naïve to specific treatment for perianal fistulising Crohn's disease including antibiotics
- Presence of an abscess or collections > 2 cm, unless resolved in the preparation procedure (week -3 to day 0).
- Presence of > 2 fistular lesions.
- Presence of > 3 external openings.
- Rectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.
- Patient who underwent surgery for the fistula other than drainage or seton placement.
- Patient with diverting stomas
- Patient with ongoing steroid treatment or treated with steroids in the last 4 weeks
- Renal impairment defined by creatinine clearance below 60 ml/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)
Hepatic impairment defined by both of the following laboratory ranges:
- Total bilirubin ≥ 1.5 x ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase(ALT) ≥ 2.5 x ULN
- Known history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.
- Malignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma.
- Current or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.
- Congenital or acquired immunodeficiencies.
- Known allergies or hypersensitivity to antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast).
- Contraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia).
- Major surgery or severe trauma within the previous 6 months.
- Pregnant or breastfeeding women.
- Patients who do not wish to or cannot comply with study procedures.
- Patients currently receiving, or having received within 3 months prior to enrolment into this clinical study, any investigational drug.
- Patients previously treated with eASCs can not be enrol into this clinical study.
- Subjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.
- Contraindication to the anaesthetic procedure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01541579
|Study Chair:||Julian Panes, MD||Hospital Clinic of Barcelona|
|Principal Investigator:||Julian Panes, MD||Hospital Clinic of Barcelona|
|Principal Investigator:||Lili Kazemi-Shirazi, Professor||Medical University of Vienna|
|Principal Investigator:||Karl Mrak, MD||Krankenhaus, St. Veit/Glan|
|Principal Investigator:||Marc Ferrante, MD||Universitaire Ziekenhuizen KU Leuven|
|Principal Investigator:||Kurt Van der Speeten, MD||Hospital Oost-Limburg, Genk|
|Principal Investigator:||Danny de Looze, Professor||Gent University Hospital|
|Principal Investigator:||Filip Baert, MD||Hospital Hartziekenhuis, Roeselare|
|Principal Investigator:||Daniel C Baumgart, Professor||Charite University, Berlin, Germany|
|Principal Investigator:||Axel Dignass, Professor||Kilikum Frankfurt|
|Principal Investigator:||Max Reinshagen, Professor||Kinikum Braunschweig|
|Principal Investigator:||Silvio Danese, MD||Instituto Clinico Humanitas IRCCS, Milano|
|Principal Investigator:||Vito Annese, MD||Azienda Ospedaliero-Universitaria Careggi, Firenze|
|Principal Investigator:||Anna Kohn, MD||Azienda Ospedaliera San Camillo-Forlanini, Rome|
|Principal Investigator:||Alfredo Papa, MD||Università Cattolica del Sacro Cuore, Rome|
|Principal Investigator:||Giacomo C Sturniolo, Professor||Azienda Ospedaliera di Padova|
|Principal Investigator:||Andrea Belluzi, MD||Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi|
|Principal Investigator:||Gabriele Riegler, Professor||University of Campania "Luigi Vanvitelli"|
|Principal Investigator:||Bas Oldenburg, MD||UMCU, Utrecht|
|Principal Investigator:||Adriaan A van Bodegraven, MD||Amsterdam UMC, location VUmc|
|Principal Investigator:||Gigs van den Brink, Professor||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|
|Principal Investigator:||María D Martín Arranz, MD||Hospital Universitario La Paz|
|Principal Investigator:||Jose M Gallardo Valverde, MD||Hospital Universitario Reina Sofía, Cordoba|
|Principal Investigator:||Javier Pérez Gisbert, MD||Hospital La Princesa (Madrid)|
|Principal Investigator:||Belén Beltrán Niclós, MD||Hospital Universitario La Fe|
|Principal Investigator:||Carlos Taxonera Samsó, MD||Hospital Clínico San Carlos, Madrid|
|Principal Investigator:||Fernando de la Portilla de Juan, MD||Hospital Virgen del Rocío, Seville|
|Principal Investigator:||Ricardo Rada Morgades, MD||Hospital Juan Ramón Jiménez, Huelva|
|Principal Investigator:||Gonzalo Gómez Gómez, MD||Hospital Universitario 12 de Octubre, Madrid|
|Principal Investigator:||Daniel Carpio López, MD||Hospital de Montecelo, Pontevedra|
|Principal Investigator:||Xavier Cortés Rizo, MD||Hospital de Sagunto, Valencia|
|Principal Investigator:||Torsten Kucharzik, Professor||Klinikum Lüneburg|
|Principal Investigator:||Andreas Sturm, Professor||Krakenhaus Walfriede, Berlin|
|Principal Investigator:||Antonio López Sanromán, MD||Hospital Universitario Ramon y Cajal|
|Principal Investigator:||Joaquín Hinojosa de Val, MD||Hospital de Manises, Valencia|
|Principal Investigator:||Xavier González Argenté, MD||Son Espases, Palma de Mallorca|
|Principal Investigator:||Maria Nachury, MD||CHRU de Lille|
|Principal Investigator:||Frank Zerbib, MD||CHU Bordeaux|
|Principal Investigator:||Stéphanie Viennot, MD||University Hospital, Caen|
|Principal Investigator:||Jean-Louis Dupas, MD||Centre Hospitalier Universitaire, Amiens|
|Principal Investigator:||Jean-Charles Grimaud, MD||CHU de Marseille|
|Principal Investigator:||Xavier Hebuterne, Professor||Centre Hospitalier Universitaire de Nice|
|Principal Investigator:||Matthieu Allez, Professor||Hôpital Saint Louis Paris|
|Principal Investigator:||Yoram Bouhnik, MD||Hôpital Beaujon, Clichy|
|Principal Investigator:||Matti Waterman, MD||Rambam MC, Haifa|
|Principal Investigator:||Shomron Ben-Horin, MD||Sheba MC, Tel Hashomer|
|Principal Investigator:||Sigal Fishman, MD||Tel Aviv Sourasky MC, Tel Aviv|
|Principal Investigator:||Eran Goldin, Professor||Sharee Zedek MC, Jerusalem|
|Principal Investigator:||Irit Avni-Biron, MD||Rabin MC, Petah Tikva|
|Principal Investigator:||Herbert Tilg, Professor||Univ.-Klinik Innsbruck|
|Principal Investigator:||Lennard Gilissen, MD||Catharina Ziekenhuis Eindhoven|
|Principal Investigator:||Carlos Pastor, MD||Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|
|Principal Investigator:||Wolfgang Kruis, Professor||Evangelisches Krankenhaus Kalk, Köln|
|Responsible Party:||Tigenix S.A.U.|
|Other Study ID Numbers:||
|First Posted:||March 1, 2012 Key Record Dates|
|Last Update Posted:||November 29, 2019|
|Last Verified:||November 2019|
Perianal fistulising Crohn's disease.
Inflammatory Bowel Diseases
Digestive System Diseases